Supernus Pharmaceuticals Revenue 2011-2023 | SUPN
Supernus Pharmaceuticals revenue from 2011 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Supernus Pharmaceuticals Annual Revenue
(Millions of US $) |
| 2023 |
$608 |
| 2022 |
$667 |
| 2021 |
$580 |
| 2020 |
$520 |
| 2019 |
$393 |
| 2018 |
$409 |
| 2017 |
$302 |
| 2016 |
$215 |
| 2015 |
$147 |
| 2014 |
$93 |
| 2013 |
$12 |
| 2012 |
$1 |
| 2011 |
$1 |
| 2010 |
$0 |
Supernus Pharmaceuticals Quarterly Revenue
(Millions of US $) |
| 2023-12-31 |
$164 |
| 2023-09-30 |
$154 |
| 2023-06-30 |
$136 |
| 2023-03-31 |
$154 |
| 2022-12-31 |
$167 |
| 2022-09-30 |
$177 |
| 2022-06-30 |
$170 |
| 2022-03-31 |
$153 |
| 2021-12-31 |
$159 |
| 2021-09-30 |
$148 |
| 2021-06-30 |
$141 |
| 2021-03-31 |
$131 |
| 2020-12-31 |
$144 |
| 2020-09-30 |
$155 |
| 2020-06-30 |
$127 |
| 2020-03-31 |
$95 |
| 2019-12-31 |
$100 |
| 2019-09-30 |
$102 |
| 2019-06-30 |
$105 |
| 2019-03-31 |
$85 |
| 2018-12-31 |
$116 |
| 2018-09-30 |
$103 |
| 2018-06-30 |
$100 |
| 2018-03-31 |
$90 |
| 2017-12-31 |
$88 |
| 2017-09-30 |
$80 |
| 2017-06-30 |
$76 |
| 2017-03-31 |
$58 |
| 2016-12-31 |
$62 |
| 2016-09-30 |
$57 |
| 2016-06-30 |
$52 |
| 2016-03-31 |
$44 |
| 2015-12-31 |
$44 |
| 2015-09-30 |
$39 |
| 2015-06-30 |
$36 |
| 2015-03-31 |
$29 |
| 2014-12-31 |
$31 |
| 2014-09-30 |
$23 |
| 2014-06-30 |
$30 |
| 2014-03-31 |
$9 |
| 2013-12-31 |
$10 |
| 2013-09-30 |
$1 |
| 2013-06-30 |
$0 |
| 2013-03-31 |
$0 |
| 2012-12-31 |
$1 |
| 2012-09-30 |
$0 |
| 2012-06-30 |
$0 |
| 2012-03-31 |
$0 |
| 2011-12-31 |
$0 |
| 2011-09-30 |
$0 |
| 2011-06-30 |
$1 |
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.604B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
